Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660144 | 0.84 | CYP4F2 (0.42) | CYP4F2CYP4A11POLBPKMLMNA | |
| SCHEMBL11296469 | 0.83 | CYP4F2 (0.50) | CYP4F2CYP4A11POLBPKMLMNA | |
| SCHEMBL6628282 | 0.83 | CYP4F2 (0.67) | CYP4F2CYP4A11CYP2C19MAPTCETP | |
| SCHEMBL14128918 | 0.80 | CYP2C19 (0.52) | CYP4F2CYP4A11CYP2C19TBXAS1LMNA | |
| SCHEMBL1106769 | 0.79 | CYP4F2 (0.45) | CYP4F2CYP4A11POLBPKMLMNA | |
| SCHEMBL187121 | 0.79 | CYP4F2 (0.45) | CYP4F2CYP4A11CYP2C19LMNACETP | |
| SCHEMBL14129083 | 0.78 | CYP4F2 (0.40) | CYP4F2CYP4A11CYP2C19TBXAS1CETP | |
| SCHEMBL6582129 | 0.78 | CYP4F2 (0.70) | CYP4F2CYP4A11TBXAS1MAPTCETP | |
| SCHEMBL27519754 | 0.78 | CYP2C19 (0.48) | CYP4F2CYP4A11CYP2C19TBXAS1 | |
| SCHEMBL186860 | 0.77 | CYP4F2 (0.48) | CYP4F2CYP4A11CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255223-B2 | Polymerizable compounds and liquid crystal media | MERCK PATENT GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| US-20120298916-A1 | POLYMERIZABLE COMPOUNDS AND LIQUID CRYSTAL MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120298916-A1 | POLYMERIZABLE COMPOUNDS AND LIQUID CRYSTAL MEDIA | RCC1, CCNB2, CCNB1 | CYP4F2 1516/4885CYP4A11 1016/4885CYP2C19 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.